SRAM
AMPH icon

Stone Ridge Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Stone Ridge Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,145
Closed -$209K – 1255
2018
Q1 		$209K Hold
11,145
– – 0.01% 1206
2017
Q4 		$214K Buy
+11,145
New +$208K 0.01% 1226

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stone Ridge Asset Management's AMPH Position: Q2 2018 in Review

Stone Ridge Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2018, closing a stake of 11,145 shares — an estimated $209K sold.

Stone Ridge Asset Management first reported a position in AMPH in Q4 2017 and held it in 2 quarters. The position peaked at $214K in Q4 2017. 114 funds tracked by Wall St. Rank hold AMPH as of Q2 2018.

  • Stone Ridge Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Stone Ridge Asset Management sold 11,145 Amphastar Pharmaceuticals shares in Q2 2018, an estimated $209K.
  • Stone Ridge Asset Management first reported a position in Amphastar Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Stone Ridge Asset Management's Amphastar Pharmaceuticals position peaked at $214K in Q4 2017.
  • 114 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2018.

Based on Stone Ridge Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.